MCID: CRV038
MIFTS: 58

Cervical Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 12 58 54 15 17 71
Squamous Cell Carcinoma of the Cervix Uteri 12 58
Squamous Cell Carcinoma of Cervix 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3744
NCIt 49 C4028
SNOMED-CT 67 254886006
ICD10 via Orphanet 33 C53.0 C53.1 C53.8
UMLS via Orphanet 72 C0279671
Orphanet 58 ORPHA213767
UMLS 71 C0279671

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology : 12 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary : Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to squamous cell carcinoma and cervical intraepithelial neoplasia. An important gene associated with Cervical Squamous Cell Carcinoma is LOC105379013 (Uncharacterized LOC105379013), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Epoetin alfa and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are digestive/alimentary and neoplasm

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.2 TP73 TP63 SERPINB3 MKI67 DAPK1 CDKN2A
2 cervical intraepithelial neoplasia 31.9 MKI67 KRT8 CDKN2A
3 cervical adenocarcinoma 31.3 RASSF1 KRAS CDKN2A
4 papilloma 31.2 TP63 RASSF1 KRT8 KRAS CDKN2A
5 cervical cancer 30.9 TYMP TP73 TP63 SKP2 SERPINB3 RASSF1
6 basaloid squamous cell carcinoma 30.8 TP63 KRT8 CDKN2A
7 endometrial adenocarcinoma 30.8 MLH1 KRAS CDKN2A
8 adenosquamous carcinoma 30.6 TP63 KRT8 KRAS
9 anal squamous cell carcinoma 30.6 TP73 RASSF1 MLH1 CDKN2A
10 small cell carcinoma 30.6 KRT8 KRAS CDKN2A
11 adenoid cystic carcinoma 30.6 TP63 RASSF1 KRT8 KRAS DAPK1 CDKN2A
12 ovary adenocarcinoma 30.5 MLH1 KRAS CDKN2A
13 uterine carcinosarcoma 30.3 MLH1 MKI67 KRT8 KRAS CDKN2A
14 transitional cell carcinoma 30.3 TP63 MLH1 MKI67 KRT8 DAPK1 CDKN2A
15 microinvasive gastric cancer 29.8 XIST SERPINB3 MLH1
16 bladder cancer 28.9 XIST TYMP TP63 RASSF1 MLH1 MKI67
17 ovarian cancer 28.7 XIST TYMP TP73 TP63 SKP2 RASSF1
18 esophageal cancer 28.7 XIST TYMP TP73 TP63 SERPINB3 RASSF1
19 microinvasive cervical squamous cell carcinoma 12.9
20 cervical verrucous carcinoma 11.4
21 cervical basaloid squamous cell carcinoma 11.4
22 cervical keratinizing squamous cell carcinoma 11.4
23 cervical lymphoepithelioma-like carcinoma 11.4
24 suppressor of tumorigenicity 3 10.8
25 cervix uteri carcinoma in situ 10.7
26 spitz nevus 10.6 MKI67 CDKN2A
27 ameloblastic carcinoma 10.6 TP63 MKI67 CDKN2A
28 oral leukoplakia 10.6 TP63 MKI67 CDKN2A
29 necrotizing sialometaplasia 10.6 TP63 MKI67
30 trachea carcinoma in situ 10.6 KRAS CDKN2A
31 vaginal tubulovillous adenoma 10.6 KRAS CDKN2A
32 atypical polypoid adenomyoma 10.6 MLH1 CDKN2A
33 pulmonary vein stenosis 10.6 TYMP MKI67
34 adenomyoma 10.6 MLH1 CDKN2A
35 inverted papilloma 10.6 SERPINB3 MKI67 CDKN2A
36 cholecystitis 10.5 RASSF1 DAPK1 CDKN2A
37 neurenteric cyst 10.5 KRT8 KRAS
38 papillary thyroid microcarcinoma 10.5 TP63 MKI67
39 descending colon cancer 10.5 SERPINB3 KRAS
40 supraglottis cancer 10.5 SERPINB3 CDKN2A
41 uterine corpus cancer 10.5 MLH1 KRAS CDKN2A
42 lung benign neoplasm 10.5 RASSF1 KRAS CDKN2A
43 tumor of exocrine pancreas 10.5 KRAS CDKN2A
44 nasal cavity cancer 10.5 SERPINB3 KRAS CDKN2A
45 anus cancer 10.5 SERPINB3 KRAS CDKN2A
46 polymorphous low-grade adenocarcinoma 10.5 TP63 MKI67
47 penile cancer 10.5 RASSF1 KRAS CDKN2A
48 respiratory system benign neoplasm 10.5 SERPINB3 KRAS CDKN2A
49 oropharynx cancer 10.5 TYMP SERPINB3 CDKN2A
50 mucinous adenocarcinoma 10.5 MLH1 KRAS CDKN2A

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CDKN2A KRAS KRT8 MLH1 RASSF1 TP63
2 neoplasm MP:0002006 9.43 CDKN2A KRAS MLH1 RASSF1 TP63 TP73
3 reproductive system MP:0005389 9.28 CDKN2A CXCL14 KRAS KRT8 MLH1 SERPINB3

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Epoetin alfa Phase 4 113427-24-0
2
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
3
leucovorin Approved Phase 3 58-05-9 6006 143
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
6
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Vinblastine Approved Phase 3 865-21-4 241903 13342
9
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
10
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
11
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
12
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
14 Mitomycins Phase 3
15 topoisomerase I inhibitors Phase 3
16 Vitamin B Complex Phase 3
17 Folic Acid Antagonists Phase 3
18 Folate Phase 3
19 Vitamin B9 Phase 3
20 Antimetabolites Phase 3
21 Anti-Bacterial Agents Phase 3
22 Antibiotics, Antitubercular Phase 3
23 Dermatologic Agents Phase 3
24
Isophosphamide mustard Phase 3 0
25 Tubulin Modulators Phase 3
26 Antimitotic Agents Phase 3
27 Albumin-Bound Paclitaxel Phase 3
28
Copper Approved, Investigational Phase 2 7440-50-8 27099
29
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
30
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
31
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
32
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
33
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Bevacizumab Approved, Investigational Phase 2 216974-75-3
38
carbamide peroxide Approved Phase 1, Phase 2 124-43-6
39
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
40
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
41
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
42
Zinc Approved, Investigational Phase 2 7440-66-6 32051
43
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
44
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
45
Indomethacin Approved, Investigational Phase 2 53-86-1 3715
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
49
Irofulven Investigational Phase 2 158440-71-2
50 Bryostatin 1 Investigational Phase 2 83314-01-6

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
2 Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer Unknown status NCT00039338 Phase 3 cisplatin
3 Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial Completed NCT02765919 Phase 3
4 A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
5 A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
6 A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes Completed NCT00003078 Phase 3 cisplatin;fluorouracil
7 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
8 A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy Active, not recruiting NCT01365156 Phase 3
9 An International Multi Center Phase III Study of Chemoradiotherapy Versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
10 Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation Terminated NCT00054067 Phase 3 cisplatin
11 Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial) Unknown status NCT02879214 Phase 2
12 Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines Unknown status NCT00794339 Phase 2 64Cu-ATSM
13 Feasibility Study of the Combination of Radiotherapy, Chemotherapy and Hyperthermia for the Treatment of Stage IIB-III-IVA Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
14 Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
15 A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB Unknown status NCT01158248 Phase 2 cisplatin
16 A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study Completed NCT02562729 Phase 2
17 A Phase II Evaluation of SU5416 (NSC 696819) in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix Completed NCT00026260 Phase 2 semaxanib
18 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
19 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
20 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
21 Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma Completed NCT00003445 Phase 2 docetaxel
22 A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix Completed NCT00087126 Phase 2 topotecan hydrochloride
23 A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231517, IND #40061) In the Treatment Of Recurrent Carcinoma Of The Cervix Completed NCT00087113 Phase 2 pemetrexed disodium
24 Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
25 Phase II Evaluation of Oxaliplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix Completed NCT00005837 Phase 2 oxaliplatin
26 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix Completed NCT00004866 Phase 2 exatecan mesylate
27 A Limited Access Phase II Trial Of Capecitabine In Advanced, Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00016926 Phase 2 capecitabine
28 Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
29 Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix Completed NCT00003017 Phase 2
30 A LIMITED ACCESS PHASE II TRIAL OF CISPLATIN AND NAVELBINE (VINORELBINE) IN ADVANCED AND RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX Completed NCT00002813 Phase 2 cisplatin;vinorelbine tartrate
31 A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT00499031 Phase 2
32 Phase I/II Study of Carboplatin in Association With Weekly Oral Topotecan in Patients With Metastatic or Recurrent Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
33 A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A) Completed NCT00025233 Phase 2
34 Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
35 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
36 A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00691301 Phase 2 cisplatin;pemetrexed disodium
37 A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer Completed NCT00278304 Phase 2
38 A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
39 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
40 A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Completed NCT01230996 Phase 1, Phase 2 Cisplatin
41 CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
42 A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00101192 Phase 2 cisplatin
43 A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
44 A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
45 ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS Completed NCT00002506 Phase 2 isotretinoin
46 Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
47 Phase II Randomized Assessing Pelvic Irradiation Combined With Cisplatin Alone or Cisplatin Plus Cetuximab in Patients With Carcinoma of the Cervix Stage IB2, II and III Completed NCT00957411 Phase 2 cisplatin
48 A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
49 A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
50 Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma Recruiting NCT03469531 Phase 2 Nimotuzumab;Cisplatin

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

Anatomical Context for Cervical Squamous Cell Carcinoma

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

40
Cervix, Uterus, Lymph Node, T Cells, Testes, Breast, Lung

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 1238)
# Title Authors PMID Year
1
Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung. 61 54
19369633 2009
2
Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma. 54 61
19366060 2009
3
[Expression of Skp2 in cervical squamous cell carcinoma and precancerous lesions and its correlation with HPV16/18 infection]. 54 61
19094580 2008
4
Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. 54 61
18191996 2008
5
Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. 54 61
18097581 2008
6
Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. 54 61
17467893 2007
7
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. 54 61
17306351 2007
8
Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. 61 54
16818688 2006
9
Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers. 54 61
16884378 2006
10
EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. 61 54
16425263 2006
11
Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study. 54 61
16803522 2006
12
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]. 54 61
16677523 2006
13
Radiation-induced cell death is independent of the apoptotic signals mediated by death-associated protein kinase in human cervical squamous cell carcinoma cells. 54 61
16142356 2005
14
Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells. 54 61
16142355 2005
15
Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. 61 54
15843547 2005
16
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma. 54 61
14614573 2004
17
P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. 61 54
14599865 2003
18
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. 54 61
12909236 2003
19
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. 54 61
11876385 2002
20
Expression of topoisomerase II and Ki-67 in cervical carcinoma--clinicopathological study using immunohistochemistry. 61 54
10752690 2000
21
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. 54 61
10810442 2000
22
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density. 54 61
10695991 2000
23
Immunohistochemical and DNA sequencing analysis on human mismatch repair gene MLH1 in cervical squamous cell carcinoma with LOH of this gene. 54 61
10769651 2000
24
Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells. 61 54
10545752 1999
25
Cervical squamous cell carcinoma coexisting with ectopic gastric mucosa treated by endoscopic submucosal dissection: A case report. 61
32454971 2020
26
lncRNA NR2F1-AS1 Regulates miR-17/SIK1 Axis to Suppress the Invasion and Migration of Cervical Squamous Cell Carcinoma Cells. 61
31994002 2020
27
A prognostic nomogram integrating novel biomarkers identified by machine learning for cervical squamous cell carcinoma. 61
32503630 2020
28
Correlation between reticulum ribosome-binding protein 1 (RRBP1) overexpression and prognosis in cervical squamous cell carcinoma. 61
32536673 2020
29
Adenoid cystic carcinoma of the Bartholin gland is not HPV-related: A case report and review of literature. 61
32345538 2020
30
The outcomes and quality of life of young patients undergoing adjuvant radiotherapy versus non-radiotherapy following surgery treating early FIGO stage cervical squamous cell cancer in southwestern China. 61
32533117 2020
31
Intravascular carcinomatosis of the brain: a report of two cases. 61
32488681 2020
32
CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma. 61
32507856 2020
33
Integrated analysis of key microRNAs /TFs /mRNAs/ in HPV-positive cervical cancer based on microRNA sequencing and bioinformatics analysis. 61
32307200 2020
34
The STAT3-miR-223-TGFBR3/HMGCS1 axis modulates the progression of cervical carcinoma. 61
32491253 2020
35
Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells. 61
32199196 2020
36
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy. 61
32493336 2020
37
WNT1, a target of miR-34a, promotes cervical squamous cell carcinoma proliferation and invasion by induction of an E-P cadherin switch via the WNT/β-catenin pathway. 61
32301035 2020
38
A fight-and-flight for life: A rare case of advanced cervical cancer in pregnancy. 61
32300631 2020
39
Atypical glandular lesions of the cervix and risk of cervical cancer. 61
31853943 2020
40
Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19. 61
32468052 2020
41
Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis. 61
32474447 2020
42
Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors. 61
32429859 2020
43
The use of miRNA in the early detection of cervical intraepithelial neoplasia. 61
32417880 2020
44
Expression and Clinical Significance of Nicotinamide N-Methyltransferase in Cervical Squamous Cell Carcinoma. 61
31033801 2020
45
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. 61
32227579 2020
46
Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma. 61
32410650 2020
47
Identification of Key Genes in Association with Progression and Prognosis in Cervical Squamous Cell Carcinoma. 61
32202912 2020
48
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma. 61
32192776 2020
49
Laparoendoscopic Single-site Radical Hysterectomy: Sufficient Exposure via Effective Suspension. 61
31518713 2020
50
Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma. 61
31709528 2020

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

9 (show top 50) (show all 907)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87033167 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 9
2 COSM88036027 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 9
3 COSM87898444 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 9
4 COSM87961314 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 9
5 COSM87912602 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 9
6 COSM88310290 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 9
7 COSM87899497 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 9
8 COSM87898723 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 9
9 COSM88057483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 17:7673745-7673745 9
10 COSM87900273 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 17:7675185-7675185 9
11 COSM87898351 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 9
12 COSM87936758 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 17:7676068-7676068 9
13 COSM87897745 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 9
14 COSM87918718 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 9
15 COSM87897839 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 9
16 COSM88192257 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 17:7673814-7673814 9
17 COSM87915380 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 17:7673790-7673790 9
18 COSM87905916 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 17:7673802-7673802 9
19 COSM87921012 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 17:7674237-7674237 9
20 COSM94089311 TOP1 cervix,NS,carcinoma,squamous cell carcinoma c.1897C>T p.Q633* 20:41118243-41118243 9
21 COSM95876207 TGFBR2 cervix,NS,carcinoma,squamous cell carcinoma c.1006G>T p.E336* 3:30672114-30672114 9
22 COSM133365371 TET2 cervix,NS,carcinoma,squamous cell carcinoma c.2659G>A p.E887K 4:105236601-105236601 9
23 COSM96852065 TENT5C cervix,NS,carcinoma,squamous cell carcinoma c.722G>T p.G241V 1:117623590-117623590 9
24 COSM90694050 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 19:1218446-1218446 9
25 COSM90692972 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 19:1220630-1220630 9
26 COSM90698131 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 19:1207082-1207082 9
27 COSM90692544 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 19:1220505-1220505 9
28 COSM100988259 SPOP cervix,NS,carcinoma,squamous cell carcinoma c.962C>T p.A321V 17:49601883-49601883 9
29 COSM93858952 ROS1 cervix,NS,carcinoma,squamous cell carcinoma c.1682C>T p.P561L 6:117389427-117389427 9
30 COSM86625005 RB1 cervix,NS,carcinoma,squamous cell carcinoma c.1630A>T p.R544* 13:48381378-48381378 9
31 COSM96920991 RAD54L cervix,NS,carcinoma,squamous cell carcinoma c.1900C>T p.R634C 1:46277847-46277847 9
32 COSM100083261 RAD50 cervix,NS,carcinoma,squamous cell carcinoma c.849G>C p.E283D 5:132587654-132587654 9
33 COSM84612906 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1681C>T p.Q561* 8:116848969-116848969 9
34 COSM84612900 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1702C>T p.Q568* 8:116848948-116848948 9
35 COSM139861925 PTPRS cervix,NS,carcinoma,squamous cell carcinoma c.5630C>G p.S1877C 19:5208249-5208249 9
36 COSM101861582 PTPRD cervix,NS,carcinoma,squamous cell carcinoma c.1693G>A p.E565K 9:8504390-8504390 9
37 COSM96842778 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 10:87952142-87952142 9
38 COSM96851558 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.65A>G p.D22G 10:87864534-87864534 9
39 COSM90594368 POLE cervix,NS,carcinoma,squamous cell carcinoma c.865G>A p.E289K 12:132676590-132676590 9
40 COSM125314212 PIK3R1 cervix,NS,carcinoma,squamous cell carcinoma c.1859A>G p.D620G 5:68296215-68296215 9
41 COSM96441717 PIK3CG cervix,NS,carcinoma,squamous cell carcinoma c.53G>A p.R18Q 7:106867614-106867614 9
42 COSM87132301 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 3:179218294-179218294 9
43 COSM87132308 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 9
44 COSM87186047 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.2924G>A p.R975K 3:179230364-179230364 9
45 COSM87132245 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 3:179234297-179234297 9
46 COSM87133243 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1357G>A p.E453K 3:179210291-179210291 9
47 COSM87132431 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>A p.M1043I 3:179234286-179234286 9
48 COSM87163290 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3145G>T p.G1049C 3:179234302-179234302 9
49 COSM87136035 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1645G>A p.D549N 3:179218315-179218315 9
50 COSM87132544 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1636C>A p.Q546K 3:179218306-179218306 9

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

7 (show all 38)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain POLS Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJA5 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain KIAA0947 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCH-VI Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain OSRF Cervical squamous cell carcinoma

Expression for Cervical Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1, type II Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T-cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4, type II Uterus - 4.45 0.000
6 SPRR3 small proline-rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin-dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine-rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine-rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor, Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C-I Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI Fanconi anemia, complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin, alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13, type I Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1, regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor, type II Uterus - 3.14 0.000
28 CFD complement factor D (adipsin) Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, polyU-specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for Cervical Squamous Cell Carcinoma

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.46 SKP2 RASSF1 MLH1 KRAS DAPK1 CDKN2A
2 12.21 TP63 RASSF1 MIR29A KRAS CDKN2A
3 11.9 TP73 TP63 SKP2 MLH1 MKI67 CDKN2A
4 11.6 TP73 KRAS CDKN2A
5 10.88 TYMP RASSF1 KRAS DAPK1 CDKN2A
6
Show member pathways
10.67 TP73 TP63 CDKN2A

GO Terms for Cervical Squamous Cell Carcinoma

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.46 TP73 TP63 SKP2 DAPK1
2 positive regulation of cellular senescence GO:2000774 9.26 KRAS CDKN2A
3 Ras protein signal transduction GO:0007265 9.13 RASSF1 KRAS CDKN2A
4 cell cycle GO:0007049 9.1 TP73 TP63 RASSF1 MLH1 MKI67 CDKN2A

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MDM2/MDM4 family protein binding GO:0097371 8.62 TP73 TP63

Sources for Cervical Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....